Oralucent is a technology company.
Oralucent has raised $1.0M across 1 funding round.
Oralucent has raised $1.0M in total across 1 funding round.
Oralucent is a consumer technology company specializing in advanced oral care products, primarily the Oralucent Pro Edition electric toothbrush that integrates sonic vibrations with red and blue light phototherapy.[1][2][4] It serves individuals seeking enhanced dental hygiene solutions, targeting problems like plaque buildup, gum disease, inflammation, teeth discoloration, bad breath, and bacteria linked to systemic health issues such as cardiovascular disease and Alzheimer's.[1][3][4] The product solves limitations of traditional toothbrushes by penetrating hard-to-reach areas between teeth and below the gum line, reducing harmful bacteria (up to 90% in preclinical data), whitening teeth when paired with gels, and promoting gum healing without chemicals or sensitivity.[2][4][5] Founded in 2019 in Long Beach, California, Oralucent has raised $1.75M in debt funding, holds 7 patents in dental equipment and oral hygiene, and generates revenue through toothbrush sales ($159), replacement heads ($24), and O2 whitening gel ($29).[1][2][3]
Oralucent emerged from five years of research and development involving dentists, scientists, and engineers, culminating in a 2022 product launch after addressing a 20-year innovation gap in toothbrushes.[1][7] The idea built on Harvard-affiliated dental research, NASA-proven red light benefits for tissue renewal, and phototherapy studies showing blue light's bacteria-killing and whitening effects.[4][7] Founders, with prior success in pediatric medicine via Colic Calm (which they sold to focus on Oralucent), applied a proven marketing formula combining dental professionals and direct consumer sales.[5] Early traction included an 18-month test market, collaboration with a major multinational, IP validation, relationships with the two largest U.S. pharmacy chains, and strong OEM/licensing interest, positioning it as a Class 1 medical device in the $11B U.S. teeth whitening and $150B global oral care markets.[1][5]
Oralucent rides the convergence of phototherapy advancements—from NASA tissue regeneration to dentist-adopted red light for sensitivity and blue light for bacteria—in the stagnant $150B oral care market lacking core toothbrush innovation for decades.[1][5][7] Timing aligns with rising consumer demand for tech-enabled personal health devices amid microbiome research linking oral bacteria to systemic diseases, plus direct-to-consumer models post-Colic Calm success.[4][5] Market forces favor it: no heavy chemicals needed, accessibility as a non-prescription device, and scalability via pharmacy partnerships and licensing to majors like those in whitening/oral care.[5] It influences the ecosystem by pioneering light therapy standards, potentially pressuring incumbents to adopt similar tech within 5 years.[1][5]
Oralucent's momentum—patent-protected tech, validated science, and efficient go-to-market—positions it to capture share in whitening and hygiene segments, with expansion via licensing, international pharmacy deals, and new consumables.[1][5] Trends like AI personalization in wearables, microbiome-focused health, and premium D2C oral tech will accelerate growth, especially as preclinical data spurs more clinical trials. Its influence may evolve from niche disruptor to industry staple, integrating light therapy into mainstream brushes and elevating oral care as a wellness gateway, much like its founders transformed pediatric remedies.
Oralucent has raised $1.0M in total across 1 funding round.
Oralucent's investors include True Wealth Ventures.
Oralucent has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in April 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2019 | $1.0M Seed | True Wealth Ventures |